Federal Register Notice: FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet 7/28 from 8 a.m. to 5 p.m. at the Hilton Washington DC/Silver Spring, Maryland Ballroom, 8727 Colesville Rd, Silver Spring, MD. The committee will discuss a King Pharmaceuticals Research and Development NDA for binodenoson injectable, lypholized solid 250 micrograms vial for a short-acting coronary vasodilator for use as an adjunct to noninvasive myocardial perfusion imaging tests to detect perfusion abnormalities in patients with known or suspected coronary artery disease. Contact Elaine Ferguson, 301–827–7001. To view this notice, click here.